Increased Serotonin 2A Receptor Availability in the Orbitofrontal Cortex of Physically Aggressive Personality Disordered Patients

Biological Psychiatry

Volumn 67, Issue 12, 2010, Pages 1154-1162

  Rosell, Daniel R ^a,b   Thompson, Judy L ^c,d   Slifstein, Mark ^c,d   Xu, Xiaoyan ^c,d   Frankle, W Gordon ^e   New, Antonia S ^a,b   Goodman, Marianne ^a,b   Weinstein, Shauna R ^a,b   Laruelle, Marc ^f   Abi Dargham, Anissa ^c,d   Siever, Larry J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Department of Medicine   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Aggression; intermittent explosive disorder; orbitofrontal cortex; personality disorder; positron emission tomography; serotonin

Indexed keywords

RADIOLIGAND; SEROTONIN 2A RECEPTOR; VOLINANSERIN; CARBON; FLUOROBENZENE; PIPERIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ADULT; AGGRESSION; AGGRESSIVENESS; ARTICLE; BIOAVAILABILITY; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPOTHESIS; IMPULSIVENESS; MALE; ORBITAL CORTEX; PASSIVE AGGRESSIVE PERSONALITY DISORDER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COMPLICATION; FRONTAL LOBE; METABOLISM; MIDDLE AGED; PERSONALITY DISORDERS; PROCEDURES; PSYCHOLOGY; RADIOASSAY; SCINTISCANNING;

ADULT; AGGRESSION; CARBON RADIOISOTOPES; FEMALE; FLUOROBENZENES; FRONTAL LOBE; HUMANS; IMPULSIVE BEHAVIOR; MALE; MIDDLE AGED; PERSONALITY DISORDERS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS;

EID: 77952886919     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.03.013     Document Type: Article

References (57)

1. McCloskey M.S., Berman M.E., Noblett K.L., and Coccaro E.F. Intermittent explosive disorder-integrated research diagnostic criteria: Convergent and discriminant validity. J Psychiatr Res 40 (2006) 231-242
2. Siever L.J. Neurobiology of aggression and violence. Am J Psychiatry 165 (2008) 449-442
3. Sakaue M., Ago Y., Sowa C., Sakamoto Y., Nishihara B., Koyama Y., et al. Modulation by 5-HT2A receptors of aggressive behavior in isolated mice. Jpn J Pharmacol 89 (2002) 89-92
4. Higgins G.A., Enderlin M., Haman M., and Fletcher P.J. The 5-HT2A receptor antagonist M100,907 attenuates motor and "impulsive-type" behaviours produced by NMDA receptor antagonism. Psychopharmacology 170 (2003) 309-319
5. Winstanley C.A., Theobald D.E., Dalley J.W., Glennon J.C., and Robbins T.W. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: Interactions with global 5-HT depletion. Psychopharmacology 176 (2004) 376-385
6. Coccaro E.F., Kavoussi R.J., Sheline Y.I., Berman M.E., and Csernansky J.G. Impulsive aggression in personality disorder correlates with platelet 5-HT2A receptor binding. Neuropsychopharmacology 16 (1991) 211-216
7. Oquendo M.A., Russo S.A., Underwood M.D., Kassir S.A., Ellis S.P., Mann J.J., and Arango V. Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide. Biol Psychiatry 59 (2006) 235-243
8. Giegling I., Hartmann A.M., Möller H.J., and Rujescu D. Anger- and aggression-related traits are associated with polymorphisms in the 5-HT-2A gene. J Affect Disord 96 (2006) 75-81
9. Nomura M., Kusumi I., Kaneko M., Masui T., Daiguji M., Ueno T., et al. Involvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior. Psychopharmacology 187 (2006) 30-35
10. Bjork J.M., Moeller F.G., Dougherty D.M., Swann A.C., Machado M.A., and Hanis C.L. Serotonin 2A receptor T102C polymorphism and impaired impulse control. Am J Med Genet 114 (2002) 336-339
11. Leyton M., Paquette V., Gravel P., Rosa-Neto P., Weston F., Diksic M., and Benkelfat C. Alpha-[11C] methyl-L-Tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters. Eur Neuropsychopharmacol 16 (2006) 220-223
12. Leyton M., Okazawa H., Diksic M., Paris J., Rosa P., Mzengeza S., et al. Brain regional alpha-[11C] methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry 158 (2001) 775-782
13. Soloff P.H., Meltzer C.C., Greer P.J., Constantine D., and Kelly T.M. A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 47 (2000) 540-547
14. Siever L.J., Buchsbaum M.S., New A.S., Spiegel-Cohen J., Wei T., Hazlett E.A., et al. d, l-fenfluramine response in impulsive personality disorder assessed with [18F] fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 20 (1999) 413-423
15. New A.S., Hazlett E.A., Buchsbaum M.S., Goodman M., Reynolds D., Mitropoulou V., et al. Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry 59 (2002) 621-629
16. New A.S., Buchsbaum M.S., Hazlett E.A., Goodman M., Koenigsberg H.W., Lo J., et al. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology 176 (2004) 451-458
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Publishing, Washington, DC
18. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Version 2.0 (1994), Biometrics Research New York State Psychiatric Institute, New York
19. Pfohl B., Blum N., and Zimmerman M. Structured Interview for DSM-IV Personality: SIDP-IV (1997), American Psychiatric Publishing, Washington, DC
20. Coccaro E.F., Harvey P.D., Kupsaw-Lawrence E., Herbert J.L., and Bernstein D.P. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatr Clin Neurosci 3 (1991) S44-S51
21. Coccaro E.F., and Kavoussi R.J. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54 (1997) 1081-1088
22. Coccaro E.F., Lee R.J., and Kavoussi R.J. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 70 (2009) 653-662
23. Kavoussi R.J., and Coccaro E.F. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 59 (1998) 676-680
24. Hollander E., Tracy K.A., Swann A.C., Coccaro E.F., McElroy S.L., and Wozniak P. Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacology 28 (2003) 1186-1197
25. Zanarini M.C., Frankenburg F.R., and Parachini E.A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65 (2004) 903-907
26. Mattes J.A. Oxcarbazepine in patients with impulsive aggression: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 25 (2005) 575-579
27. Buss A.H., and Durkee A. An inventory for assessing different kinds of hostility. J Consult Psychol 21 (1957) 343-349
28. Buss A.H., and Perry M. The aggression questionnaire. J Pers Soc Psychol 63 (1992) 452-459
29. Patton J.H., Stanford M.S., and Barratt E.S. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51 (1995) 768-774
30. Harvey P.D., Greenberg B.R., and Serper M.R. The affective lability scales: Development, reliability, and validity. J Clin Psychol 45 (1989) 786-793
31. Beck A.T., and Steer R.A. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 40 (1984) 1365-1367
32. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27 (2007) 1533-1539
33. Benjamini Y., and Hochberg Y. Controlling the false discovery rate-A practical and powerful approach to multiple testing. J R Statist Soc B 57 (1995) 289-300
34. Soloff P.H., Price J.C., Meltzer C.C., Fabio A., Frank G.K., and Kaye W.H. 5HT2A receptor binding is increased in borderline personality disorder. Biol Psychiatry 62 (2007) 580-587
35. Meyer J.H., Wilson A.A., Rusjan P., Clark M., Houle S., Woodside S., et al. Serotonin2A receptor binding potential in people with aggressive and violent behaviour. J Psychiatry Neurosci 33 (2008) 499-508
36. Hare R.D., Hart S.D., and Harpur T.J. Psychopathy and the DSM-IV criteria for antisocial personality disorder. J Abnorm Psychol 100 (1991) 391-398
37. Herpertz S.C., Werth U., Lukas G., Qunaibi M., Schuerkens A., Kunert H.J., et al. Emotion in criminal offenders with psychopathy and borderline personality disorder. Arch Gen Psychiatry 58 (2001) 737-745
38. Birbaumer N., Veit R., Lotze M., Erb M., Hermann C., Grodd W., and Flor H. Deficient fear conditioning in psychopathy: A functional magnetic resonance imaging study. Arch Gen Psychiatry 62 (2005) 799-805
39. Herpertz S.C., Dietrich T.M., Wenning B., Krings T., Erberich S.G., Willmes K., et al. Evidence of abnormal amygdala functioning in borderline personality disorder: A functional MRI study. Biol Psychiatry 50 (2001) 292-298
40. Donegan N.H., Sanislow C.A., Blumberg H.P., Fulbright R.K., Lacadie C., Skudlarski P., et al. Amygdala hyperreactivity in borderline personality disorder: Implications for emotional dysregulation. Biol Psychiatry 54 (2003) 1284-1293
41. Haller J., and Kruk M.R. Normal and abnormal aggression: Human disorders and novel laboratory models. Neurosci Biobehav Rev 30 (2006) 292-303
42. Mitchell D.G., Richell R.A., Leonard A., and Blair R.J. Emotion at the expense of cognition: Psychopathic individuals outperform controls on an operant response task. J Abnorm Psychol 115 (2006) 559-566
43. Haller J., Mikics E., Halász J., and Tóth M. Mechanisms differentiating normal from abnormal aggression: Glucocorticoids and serotonin. Eur J Pharmacol 526 (2005) 89-100
44. Haller J., Horváth Z., and Bakos N. The effect of buspirone on normal and hypoarousal-driven abnormal aggression in rats. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 27-31
45. Haller J., Tóth M., and Halász J. The activation of raphe serotonergic neurons in normal and hypoarousal-driven aggression: A double labeling study in rats. Behav Brain Res 161 (2005) 88-94
46. Schiller L., Jähkel M., Kretzschmar M., Brust P., and Oehler J. Autoradiographic analyses of 5-HT1A and 5-HT2A receptors after social isolation in mice. Brain Res 980 (2003) 169-178
47. Wu J., Kramer G.L., Kram M., Steciuk M., Crawford I.L., and Petty F. Serotonin and learned helplessness: A regional study of 5-HT1A, 5-HT2A receptors and the serotonin transport site in rat brain. J Psychiatr Res 33 (1999) 17-22
48. Dwivedi Y., Mondal A.C., Payappagoudar G.V., and Rizavi H.S. Differential regulation of serotonin (5HT) 2A receptor mRNA and protein levels after single and repeated stress in rat brain: Role in learned helplessness behavior. Neuropharmacology 48 (2005) 204-214
49. Günther L., Liebscher S., Jähkel M., and Oehler J. Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice. Eur J Pharmacol 593 (2008) 49-61
50. Rios M., Lambe E.K., Liu R., Teillon S., Liu J., Akbarian S., et al. Severe deficits in 5-HT2A -mediated neurotransmission in BDNF conditional mutant mice. J Neurobiol 66 (2006) 408-420
51. Sumner B.E., D'Eath R.B., Farnworth M.J., Robson S., Russell J.A., Lawrence A.B., et al. Early weaning results in less active behaviour, accompanied by lower 5-HT1A and higher 5-HT2A receptor mRNA expression in specific brain regions of female pigs. Psychoneuroendocrinology 33 (2008) 1077-1092
52. Van Oekelen D., Luyten W.H., and Leysen J.E. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72 (2003) 2429-2449
53. Eison A.S., and Mullins U.L. Regulation of central 5-HT2A receptors: A review of in vivo studies. Behav Brain Res 73 (1996) 177-181
54. Gray J.A., and Roth B.L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56 (2001) 441-451
55. Stockmeier C.A., and Kellar K.J. In vivo regulation of the serotonin-2 receptor in rat brain. Life Sci 38 (1986) 117-127
56. Jakab R.L., and Goldman-Rakic P.S. 5-hydroxytryptamine 2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A 95 (1998) 735-740
57. Jakab R.L., and Goldman-Rakic P.S. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 417 (2000) 337-348